Please provide your email address to receive an email when new articles are posted on . Lymphopenia at diagnosis or during follow-up can predict OS among patients with multiple myeloma. Researchers ...
Impact of venous thromboembolism on survival in multiple myeloma patients receiving bispecific antibody therapy: Insights from real-world data. Risk of second primary hematological malignancy post CAR ...
Measuring the lymphocytes — white blood cells that fight infection — in a patient’s blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to ...
(A) Principal component analysis (PCA) of lymphocyte subsets and factors such as age in Control, LC, and LC-PTB groups, and the joint analysis of LC & LC-PTB. PC1 and PC2 represent the first and ...
CD44 and CD271 expression and chemoresistance in BRAF V600E/K mutation–positive melanoma. Note. PFS: Progression free survival; OS: Overall Survival; irAE: immune related adverse events; LDH: lactate ...
OBJECTIVES: To identify risk factors for DMF-induced lymphopenia and characterize its impact on T lymphocyte subsets in MS patients. METHODS: We performed a retrospective analysis of 194 RRMS patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results